1
/
의
1
AntibodySystem
SKU(재고 관리 코드):KDX00401
Obiltoxaximab ELISA Kit
Obiltoxaximab ELISA Kit
Catalog No.: KDX00401
| Catalog No. | KDX00401 |
|---|---|
| Product name | Obiltoxaximab ELISA Kit |
| Size | 96 T |
| Description | PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Bacillus anthracis PA has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Obiltoxaximab in the sample competitively binds to the pre-coated protein with biotin-labeled Obiltoxaximab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Obiltoxaximab bound in the initial step. The color development is stopped and the intensity of the color is measured. |
| Applications | Used for the quantitative determination of Obiltoxaximab concentration in serum and plasma. |
| Stability and Storage | When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. |
| Detection method | Colorimetric |
| Precision | CV<20% |
| Sample type | Plasma, Serum |
| Assay type | Quantitative |
| Sensitivity | 4.66 ng/mL |
| Range | 12.5 - 800 ng/mL |
| Recovery | 80-120% |
| Background | Obiltoxaximab (ETI-204, trade name Anthim) is an affinity-enhanced, chimeric IgG1 kappa monoclonal antibody (mAb) developed by Elusys Therapeutics and the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) for the prevention and treatment of inhalational anthrax due to Bacillus anthracis. Obiltoxaximab binds the protective antigen (PA) component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa. Obiltoxaximab has been designed to neutralize the free protective antigen of B. anthracis, thereby inhibiting the lethal effects of anthrax toxins. In March 2016, intravenous obiltoxaximab was approved in the USA for the treatment (in combination with appropriate antibacterial drugs) and prophylaxis of inhalational anthrax. |
| Alternative Names | ETI-204, CAS: 1351337-07-9 |
| Shipping | 2-8 ℃ |
| Note | For Research Use Only. |
Share
